Cadrenal Therapeutics, Inc. Earnings Per Share (Basic)
Cadrenal Therapeutics, Inc. (CVKD) reported Earnings Per Share (Basic) of -$1.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$1.14.
- Cadrenal Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$1.04.
- Cadrenal Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$1.43.
- Cadrenal Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$1.31.
- Cadrenal Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$6.64.
- Cadrenal Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$8.73.
- Cadrenal Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$9.29.
| Period end | Earnings Per Share, Basic 2 month | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 5 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 8 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 11 month | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.14 10-Q · filed 2026-08-13 | -$2.19 10-Q · filed 2026-08-13 | -$3.57 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$4.87 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||||||
| 2026-03-31 | -$1.04 10-Q · filed 2026-05-07 | -$2.44 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.75 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$5.57 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||||||
| 2025-12-31 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$2.75 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$4.60 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$6.64 10-K · filed 2026-03-31 | ||||||||
| 2025-09-30 | -$1.31 10-Q · filed 2025-11-10 | -$3.17 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$5.23 10-Q · filed 2025-11-10 | -$8.19 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||||||
| 2025-06-30 | -$1.87 10-Q · filed 2026-08-13 | -$3.95 10-Q · filed 2026-08-13 | -$7.05 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$9.28 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||||||
| 2025-03-31 | -$2.09 10-Q · filed 2026-05-07 | -$5.32 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$7.60 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$9.89 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||||||||
| 2024-12-31 | -$3.57 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$5.79 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$8.06 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$8.73 10-K · filed 2026-03-31 | ||||||||
| 2024-09-30 | -$2.18 10-Q · filed 2025-11-10 | -$4.42 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$5.24 10-Q · filed 2025-11-10 | -$5.99 10-Q · filed 2024-11-07 | ||||||||
| 2024-06-30 | -$2.24 10-Q · filed 2025-08-11 | -$0.15 10-Q · filed 2024-08-07 | -$3.80 10-Q · filed 2025-08-11 | -$0.25 10-Q · filed 2024-08-07 | ||||||||
| 2024-03-31 | -$1.56 10-Q · filed 2025-05-08 | -$0.10 10-Q · filed 2024-05-09 | ||||||||||
| 2023-12-31 | -$9.29 10-K · filed 2025-03-13 | -$0.62 10-K · filed 2024-03-11 | ||||||||||
| 2023-09-30 | -$1.01 10-Q · filed 2024-11-07 | -$0.07 10-Q · filed 2023-11-09 | -$8.56 10-Q · filed 2024-11-07 | -$0.57 10-Q · filed 2023-11-09 | ||||||||
| 2023-06-30 | -$0.09 10-Q · filed 2024-08-07 | -$0.55 10-Q · filed 2024-08-07 | ||||||||||
| 2023-03-31 | -$0.48 10-Q · filed 2024-05-09 | |||||||||||
| 2022-12-31 | -$0.85 10-K · filed 2024-03-11 | |||||||||||
| 2022-09-30 | -$0.13 10-Q · filed 2023-11-09 | -$0.22 10-Q · filed 2023-11-09 | ||||||||||
| 2022-06-30 | -$0.07 10-Q · filed 2023-08-10 | -$0.09 10-Q · filed 2023-08-10 | ||||||||||
| 2022-03-31 | -$0.02 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |